268 related articles for article (PubMed ID: 34587429)
1. Nanocarriers for Anticancer Drug Targeting: Recent Trends and Challenges.
Dahiya S; Dahiya R; Hernández E
Crit Rev Ther Drug Carrier Syst; 2021; 38(6):49-103. PubMed ID: 34587429
[TBL] [Abstract][Full Text] [Related]
2. Endogenous pH-responsive nanoparticles with programmable size changes for targeted tumor therapy and imaging applications.
Wu W; Luo L; Wang Y; Wu Q; Dai HB; Li JS; Durkan C; Wang N; Wang GX
Theranostics; 2018; 8(11):3038-3058. PubMed ID: 29896301
[TBL] [Abstract][Full Text] [Related]
3. Advancements in pH-responsive nanocarriers: enhancing drug delivery for tumor therapy.
Chen Z; Wang X; Zhao N; Chen H; Guo G
Expert Opin Drug Deliv; 2023; 20(11):1623-1642. PubMed ID: 38059646
[TBL] [Abstract][Full Text] [Related]
4. Renal clearable nanocarriers: Overcoming the physiological barriers for precise drug delivery and clearance.
Peng C; Huang Y; Zheng J
J Control Release; 2020 Jun; 322():64-80. PubMed ID: 32194171
[TBL] [Abstract][Full Text] [Related]
5. Recent Trends in Nanocarrier-Based Drug Delivery System for Prostate Cancer.
Kumar A; Lunawat AK; Kumar A; Sharma T; Islam MM; Kahlon MS; Mukherjee D; Narang RK; Raikwar S
AAPS PharmSciTech; 2024 Mar; 25(3):55. PubMed ID: 38448649
[TBL] [Abstract][Full Text] [Related]
6. Inorganic nanocarriers for siRNA delivery for cancer treatments.
Kandasamy G; Maity D
Biomed Mater; 2024 Jan; 19(2):. PubMed ID: 38181441
[TBL] [Abstract][Full Text] [Related]
7. Cell-nanocarrier drug delivery system: a promising strategy for cancer therapy.
Yang J; Shi X; Kuang Y; Wei R; Feng L; Chen J; Wu X
Drug Deliv Transl Res; 2024 Mar; 14(3):581-596. PubMed ID: 37721694
[TBL] [Abstract][Full Text] [Related]
8. A Comprehensive Review on Nanoparticles as a Targeted Delivery System for the Treatment of Lung Cancer.
Gupta T; Varanwal A; Nema P; Soni S; Iyer AK; Das R; Soni V; Kashaw SK
Anticancer Agents Med Chem; 2024; 24(3):157-168. PubMed ID: 38013441
[TBL] [Abstract][Full Text] [Related]
9. Targeted drug delivery systems for matrix metalloproteinase-responsive anoparticles in tumor cells: A review.
Guo F; Du Y; Wang Y; Wang M; Wang L; Yu N; Luo S; Wu F; Yang G
Int J Biol Macromol; 2024 Feb; 257(Pt 1):128658. PubMed ID: 38065446
[TBL] [Abstract][Full Text] [Related]
10. Advances in Targeting Drug Biological Carriers for Enhancing Tumor Therapy Efficacy.
Xia D; Li J; Feng L; Gao Z; Liu J; Wang X; Hu Y
Macromol Biosci; 2023 Dec; 23(12):e2300178. PubMed ID: 37466216
[TBL] [Abstract][Full Text] [Related]
11. Long-circulating nanoparticles as passive targeting nanocarriers for the treatment of thrombosis.
Li J; Lu K; Sun S; Peng J; Zhao L
Nanoscale; 2024 Mar; 16(12):6132-6141. PubMed ID: 38444355
[TBL] [Abstract][Full Text] [Related]
12. Recent progress in lactate oxidase-based drug delivery systems for enhanced cancer therapy.
Li L; Yue T; Feng J; Zhang Y; Hou J; Wang Y
Nanoscale; 2024 May; 16(18):8739-8758. PubMed ID: 38602362
[TBL] [Abstract][Full Text] [Related]
13. Lipid-Based Nanocarriers for Targeted Gene Delivery in Lung Cancer Therapy: Exploring a Novel Therapeutic Paradigm.
Beigi A; Naghib SM; Matini A; Tajabadi M; Mozafari MR
Curr Gene Ther; 2024 May; ():. PubMed ID: 38778601
[TBL] [Abstract][Full Text] [Related]
14. Nanocarrier-based localized and effective treatment of renal disorders: currently employed targeting strategies.
Ullah S; Burki S; Munir AB; Yousaf G; Shafique M
Nanomedicine (Lond); 2024 Feb; 19(4):345-361. PubMed ID: 38293889
[TBL] [Abstract][Full Text] [Related]
15. Protein corona on brain targeted nanocarriers: Challenges and prospects.
Jiang K; Yu Y; Qiu W; Tian K; Guo Z; Qian J; Lu H; Zhan C
Adv Drug Deliv Rev; 2023 Nov; 202():115114. PubMed ID: 37827336
[TBL] [Abstract][Full Text] [Related]
16. Nanotechnology and Glycosaminoglycans: Paving the Way Forward for Ovarian Cancer Intervention.
Hoosen Y; Pradeep P; Kumar P; du Toit LC; Choonara YE; Pillay V
Int J Mol Sci; 2018 Mar; 19(3):. PubMed ID: 29510526
[TBL] [Abstract][Full Text] [Related]
17. Exploring nanocarriers as innovative materials for advanced drug delivery strategies in onco-immunotherapies.
Tiwari P; Shukla RP; Yadav K; Panwar D; Agarwal N; Kumar A; Singh N; Bakshi AK; Marwaha D; Gautam S; Rai N; Mishra PR
J Mol Graph Model; 2024 May; 128():108702. PubMed ID: 38219505
[TBL] [Abstract][Full Text] [Related]
18. Nanomedicines in B cell-targeting therapies.
Wang J; Yang J; Kopeček J
Acta Biomater; 2022 Jan; 137():1-19. PubMed ID: 34687954
[TBL] [Abstract][Full Text] [Related]
19. Empowering lung cancer treatment: Harnessing the potential of natural phytoconstituent-loaded nanoparticles.
Siddiquee T; Bhaskaran NA; Nathani K; Sawarkar SP
Phytother Res; 2024 May; ():. PubMed ID: 38806412
[TBL] [Abstract][Full Text] [Related]
20. Hybrid Nanocarriers for Neurological Disorders: Diagnostic & Therapeutic Approach.
Mishra A; Ahsan R; Islam A; Tiwari RK; Dash PP
Recent Pat Nanotechnol; 2024; 18(2):164-178. PubMed ID: 36028962
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
